MDM4 and cancer: Therefore, this study not only validates MDMX degradation as a promising clinical strategy for anti-cancer therapy, but, more importantly, provides a feasible method to translate peptide-derived PROTACs into a potential drug candidate, and likely reinvigorates their discovery efforts for a great variety of diseases.